Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 17Unknown 2Active not recruiting 2Terminated 1Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 146Breast Neoplasms 143Neoplasms 142Colorectal Neoplasms 135Recurrence 104Ovarian Neoplasms 100Pancreatic Neoplasms 81Lung Neoplasms 81Multiple Myeloma 80Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Lymphoma, B-Cell 53Endometrial Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Advanced Solid Malignancies × Clear all
NCT07368478 2026-01-26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Biocity Biopharmaceutics Co., Ltd.

Phase 1 Recruiting
180 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡